Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry?

Ian E Haines and Ian N Olver
Med J Aust 2008; 189 (5): 263-266.


  • Ian E Haines1,2
  • Ian N Olver3

  • 1 Melbourne Oncology Group, Cabrini Health, Melbourne, VIC.
  • 2 Department of Medicine, Monash University, Melbourne, VIC.
  • 3 Cancer Council Australia, Sydney, NSW.


Competing interests:

None identified.

  • 1. Van Der Weyden MB. Confronting conflict of interest in research organisations: time for national action [editorial]. Med J Aust 2001; 175: 396-397. <MJA full text>
  • 2. Van Der Weyden MB. Clinical practice guidelines: time to move the debate from the how to the who [editorial]. Med J Aust 2002; 176: 304-305. <MJA full text>
  • 3. Kamien M. Confronting conflict of interest in research organisations: time for national action [letter]. Med J Aust 2002; 176: 243. <MJA full text>
  • 4. Breen KJ. The medical profession and the pharmaceutical industry: when will we open our eyes? Med J Aust 2004; 180: 409-410. <MJA full text>
  • 5. Chew M. What conflict of interest [editorial]? Med J Aust 2004; 181: 4-5. <MJA full text>
  • 6. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Studies 2005; 34: 1-25.
  • 7. Parascandola M. A turning point for conflicts of interest: the controversy over the National Academy of Sciences’ first conflicts of interest disclosure policy. J Clin Oncol 2007; 25: 3774-3779.
  • 8. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003; 290: 252-255.
  • 9. Riechelmann RP, Wang S, O’Carroll A, Krzyzanowska K. Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 2007; 25: 4642-4647.
  • 10. Tuech JJ, Moutel G, Pessaux P, et al. Disclosure of competing financial interests and role of sponsors in phase II clinical trials. Eur J Cancer 2005; 41: 2237-2240.
  • 11. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005; 182: 557-560. <MJA full text>
  • 12. Hampson LA, Joffe S, Fowler R, et al. Frequency, type and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 2007; 25: 3609-3614.
  • 13. Johnston KL, Go RS. Financial conflicts of interest among ASCO annual meeting abstract authors, speakers, and planners. J Natl Cancer Inst 2007; 99: 1415-1416.
  • 14. Campbell EG. Doctors and drug companies — scrutinizing influential relationships. N Engl J Med 2007; 357: 1796-1797.
  • 15. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic–industry relationships. JAMA 2007; 298: 1779-1786.
  • 16. Gray SW, Hlubocky FJ, Ratain MJ, Daugherty CK. Attitudes toward research participation and investigator conflicts of interest among cancer patients participating in early phase clinical trials. J Clin Oncol 2007; 25: 3488-3494.
  • 17. Gillis J. A hospital’s conflict of interest: patients weren’t told of stake in cancer drug. Washington Post 2002; 30 Jun: A1, A14.
  • 18. Hampson LA, Agrawal M, Joffe S, et al. Patients’ views on financial conflicts of interest in cancer research trials. N Engl J Med 2006; 355: 2330-2337.
  • 19. Wells RJ. Secrecy and integrity in clinical trials. J Clin Oncol 2008; 26: 680-682.
  • 20. Knox KS, Adams JR, Djulbegovic B, et al. Reporting and dissemination of industry versus non-profit sponsored economic analysis of six novel drugs used in oncology. Ann Oncol 2000; 11: 1591-1595.
  • 21. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000; 356: 635-638.
  • 22. Fyfe M. Drug companies “manipulating trials”. The Age (Melbourne) 2006; 7 Aug: 1.
  • 23. American Society of Clinical Oncology. Interactions with the investment industry: practical and ethical implications. J Clin Oncol 2007; 25: 338-340.
  • 24. Steinbrook R. Guidance for guidelines. N Engl J Med 2007; 356: 331-333.
  • 25. Tattersall MHN, Kerridge IH. Doctors behaving badly [editorial]? Med J Aust 2006; 185: 299-300. <MJA full text>
  • 26. Ozols RF, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention and screening — a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25: 146-162.
  • 27. Abraham J. The pharmaceutical industry as a political player. Lancet 2002; 360: 1498-1502.
  • 28. McLean T, Burke K. Call to name GPs who take drug perks. Sydney Morning Herald 2007; 1 Nov: 3.
  • 29. Samuel G. Keeping track of what the doctor ordered [opinion]. The Age (Melbourne) 2006; 28 Jul: 17.
  • 30. Fyfe M, Nader C, Baker R. Conflict of interest problem endemic: specialist. The Age (Melbourne) 2006; 7 Aug. (accessed Jul 2008).
  • 31. Bala-Miller P, Macmullan J, Upchurch L. Drugs, doctors and dinners. How drug companies influence health in the developing world. London: Consumers International, 2007. (accessed Feb 2008).
  • 32. Kassirer JP. On the take: how medicine’s complicity with big business can endanger your health. New York: Oxford University Press, 2005: 251.
  • 33. Association of the British Pharmaceutical Industry. ABPI annual report for 1970–1971. London: ABPI, 1971.
  • 34. Godlee F. Doctors and the drug industry [editorial]. BMJ 2008; 336: 5 Jan.
  • 35. Federal Court of Australia. Application by Medicines Australia Inc [2007] ACompT 4. (accessed Feb 2008).
  • 36. Cresswell A. Deloitte appointed to monitor drug company freebies. The Australian 2008; 26 Jan: 27.,25197,23110350-23289,00.html (accessed Jul 2008).
  • 37. Feder BJ. New focus of inquiry into bribes: doctors. New York Times 2008; 22 Mar. (accessed Jul 2008).
  • 38. Haines IE. A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies. J Clin Oncol 2007; 25: e31-e32.
  • 39. Haines IE. Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer. J Clin Oncol 2007; 25: e24-e25.
  • 40. Haines IE. Doubts about whether docetaxel, cisplatin, plus fluorouracil has any benefit in advanced gastric cancer. J Clin Oncol 2007; 25: 5528-5529.
  • 41. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239.
  • 42. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
  • 43. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
  • 44. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
  • 45. Kolata G. Citing ethics, some doctors are rejecting industry pay. New York Times 2008; 15 Apr. (accessed Jul 2008).
  • 46. Harris G. Group urges ban on medical giveaways. New York Times 2008; 28 Apr. (accessed Jul 2008).
  • 47. Black H. Dealing in drugs. Lancet 2004; 364: 1655-1656.
  • 48. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2: e138.
  • 49. Association of American Medical Colleges. Industry funding of medical education. Report of an AAMC Task Force. Washington, DC: AAMC, 2008. (accessed Jun 2008).
  • 50. Fava GA. Financial conflicts of interest in psychiatry. World Psychiatry 2007; 6: 19-24.
  • 51. Giles J. Drug trials: stacking the deck. Nature 2006; 440: 270-272.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.